Pascale Tomasini

Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients

Myriam Delaunay, J. Cadranel, Amélie Lusque et al. · European Respiratory Journal · 2017 · 416 citations · Full text

Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study

Antonio Passaro, Jing Wang, Yan Wang et al. · Annals of Oncology · 2023 · 347 citations · Full text

Rare EGFR exon 18 and exon 20 mutations in non-small-cell lung cancer on 10 117 patients: a multicentre observational study by the French ERMETIC-IFCT network

Michèle Beau‐Faller, Nathalie Prim, Anne-Marie Ruppert et al. · Annals of Oncology · 2013 · 312 citations · Full text

Rare Egfr, Non-small-cell Lung Cancer, Medicine +8

Prognostic and predictive effects of TP53 co-mutation in patients with EGFR -mutated non-small cell lung cancer (NSCLC)

Catherine Labbé, Michael Cabanero, Grzegorz Korpanty et al. · Lung Cancer · 2017 · 246 citations

Medicine, Pathology, Cancer Genomics +7

Efficacy of Immune Checkpoint Inhibitors in KRAS-Mutant Non-Small Cell Lung Cancer (NSCLC)

A. Jeanson, Pascale Tomasini, M. Souquet-Bressand et al. · Journal of Thoracic Oncology · 2019 · 221 citations · Full text

Medicine, Immune Checkpoint Inhibitors, Immunology +7